Table 2. Number of patients (N), observed number (O), SIR, AER per 10 000 person-years and 10-, and 20-year cumulative incidence (%) for metachronous CTGCTs according to histological type age, period of diagnosis and treatment of the primary TGCT.
| At risk at 6 months | Person-time (years) | All CTGCT a | SIR (95% CI) | AER (95% CI) | At risk at 10 years | CTGCT at 10 years | 10-year cumulative incidence (95% CI) | At risk at 20 years | CTGCT at 20 years | 20-year cumulative incidence (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seminoma and non-seminoma combined | |||||||||||
| All patients | 3608 | 63 635 | 77 | 17.6 (13.9–22.0) | 11.4 (8.9–14.4) | 2963 | 49 | 1.4 (1.0–1.8) | 1554 | 75 | 2.2 (1.8–2.8) |
| Age | |||||||||||
| <30 | 1451 | 25 633 | 40 | 14.9 (10.6–20.3) | 14.6 (10.1–20.2) | 1198 | 23 | 1.6 (1.1–2.4) | 640 | 40 | 3.0 (2.2–4.1) |
| 30–39 | 1180 | 21 716 | 26 | 20.8 (13.6–30.5) | 11.4 (7.2–17.0) | 995 | 20 | 1.7 (1.1–2.6) | 536 | 24 | 2.2 (1.4–3.2) |
| ⩾40 | 977 | 16 286 | 11 | 25.3 (12.6–45.3) | 6.5 (3.1–11.8) | 770 | 6 | 0.6 (0.3–1.3) | 378 | 11 | 1.2 (0.6–2.0) |
| Treatment period | |||||||||||
| 1965–1975 | 725 | 14 633 | 22 | 41.1 (25.8–62.3) | 14.7 (9.0–22.4) | 490 | 14 | 1.9 (1.1–3.2) | 409 | 21 | 2.9 (1.9–4.3) |
| 1976–1985 | 1403 | 28 168 | 27 | 15.8 (10.4–23.0) | 9.0 (5.7–13.3) | 1184 | 13 | 0.9 (0.5–1.6) | 985 | 26 | 1.9 (1.3–2.7) |
| 1986–1995 | 1480 | 20 834 | 28 | 13.2 (8.7–19.0) | 12.4 (7.9–18.4) | 1289 | 22 | 1.5 (1.0–2.2) | 160 | 28 | 2.0 (1.4–2.9) |
| Total treatmentb | |||||||||||
| Surgeryc | 2127 | 41 274 | 62 | 25.8 (19.7–33.0) | 14.4 (10.9–18.7) | 1859 | 40 | 1.9 (1.4–2.6) | 1055 | 60 | 3.0 (2.3–3.9) |
| Platinum-based CTc | 1149 | 18 182 | 13 | 7.5 (4.0–12.9) | 6.2 (2.9–11.3) | 950 | 8 | 0.7 (0.3–1.3) | 372 | 13 | 1.2 (0.7–1.2) |
| Other CTc | 332 | 4179 | 2 | 8.5 (1.0–30.7) | 4.2 (0.2–16.7) | 154 | 1 | 0.3 (0.0–1.6) | 127 | 2 | 0.6 (0.1–2.1) |
| Follow-up interval (years)d,e | |||||||||||
| 0.5–4 | 3608 | 14 817 | 24 | 21.2 (13.6–31.5) | 15.4 (9.6–23.3) | ||||||
| 5–9 | 3136 | 15 338 | 25 | 19.7 (12.8–29.1) | 15.5 (9.7–23.2) | ||||||
| 10–14 | 2963 | 13 416 | 17 | 16.7 (9.7–26.7) | 11.9 (6.6–19.5) | ||||||
| 15–19 | 2313 | 9747 | 9 | 15.7 (7.2–29.8) | 8.6 (3.6–16.9) | ||||||
| 20–24 | 1554 | 5888 | 2 | 7.8 (0.9–28.2) | 3.0 (−0.2 to 11.8) | ||||||
| Seminoma | |||||||||||
| All patients | 1675 | 30 531 | 39 | 24.9 (17.7–34.0) | 12.3 (8.6–17.0) | 1413 | 25 | 1.5 (1.0–2.2) | 744 | 37 | 2.4 (1.7–3.2) |
| Age | |||||||||||
| <30 | 323 | 6060 | 13 | 22.5 (12.0–38.5) | 20.5 (10.5–35.7) | 280 | 8 | 2.5 (1.2–4.7) | 156 | 13 | 4.3 (2.4–7.0) |
| 30–39 | 630 | 12 074 | 17 | 25.7 (15.0–41.1) | 13.5 (7.7–22.0) | 554 | 12 | 1.9 (1.1–3.3) | 294 | 15 | 2.6 (1.5–4.2) |
| ⩾40 | 722 | 12 397 | 9 | 27.4 (12.5–52.0) | 7.0 (3.1–13.5) | 579 | 5 | 0.7 (0.3–1.6) | 294 | 9 | 1.3 (0.6–2.4) |
| Treatment period | |||||||||||
| 1965–1975 | 393 | 8880 | 14 | 48.6 (26.6–81.6) | 15.4 (8.3–26.1) | 306 | 7 | 1.8 (0.8–3.5) | 252 | 13 | 3.3 (1.9–5.4) |
| 1976–1985 | 613 | 12 381 | 11 | 20.3 (10.1–36.2) | 8.4 (4.0–15.5) | 534 | 7 | 1.2 (0.5–2.3) | 416 | 10 | 1.7 (0.9–3.0) |
| 1986–1995 | 669 | 9270 | 14 | 19.9 (10.4–31.9) | 14.3 (7.5–24.5) | 573 | 11 | 1.7 (0.9–2.9) | 76 | 14 | 2.3 (1.3–3.7) |
| Total treatmentb | |||||||||||
| Surgeryc | 1387 | 26 654 | 37 | 27.8 (19.6–38.6) | 13.4 (9.3–18.6) | 1213 | 24 | 1.8 (1.2–2.6) | 673 | 35 | 2.7 (1.9–3.7) |
| Platinum-based CTc,f | 209 | 3148 | 1 | 4.9 (0.1–27.5) | 2.5 (−0.6 to 17.1) | 172 | 0 | 0.0 | 51 | 1 | 0.5 (0.0–2.6) |
| Other CTc | 79 | 729 | 1 | 29.8 (0.8–165.8) | 13.2 (−0.1 to 75.9) | 28 | 1 | 1.3 (0.1–6.1) | 20 | 1 | 1.3 (0.1–6.1) |
| Follow-up interval (years)d,e | |||||||||||
| 0.5–4 | 1675 | 7123 | 13 | 27.9 (14.8–47.7) | 17.6 (9.1–30.6) | ||||||
| 5–9 | 1515 | 7388 | 12 | 25.9 (13.4–45.3) | 15.6 (7.8–27.7) | ||||||
| 10–14 | 1413 | 6342 | 9 | 27.0 (12.3–51.2) | 13.7 (6.0–26.4) | ||||||
| 15–19 | 1080 | 4585 | 3 | 16.9 (3.5–49.4) | 6.2 (1.0–18.7) | ||||||
| 20–24 | 744 | 2789 | 2 | 24.6 (3.0–89.0) | 6.9 (0.6–25.6) | ||||||
| Non-seminoma | |||||||||||
| All patients | 1933 | 33 104 | 38 | 13.6 (9.6–18.6) | 10.6 (7.3–14.9) | 1550 | 24 | 1.3 (0.8–1.8) | 810 | 38 | 2.2 (1.5–2.9) |
| Age | |||||||||||
| <30 | 1128 | 19 573 | 27 | 12.8 (8.6–19.1) | 12.7 (8.0–19.0) | 918 | 15 | 1.3 (0.8–2.2) | 484 | 27 | 2.7 (1.8–3.9) |
| 30–39 | 550 | 9641 | 9 | 15.3 (7.0–29.5) | 8.7 (3.7–17.1) | 441 | 8 | 1.5 (0.7–2.8) | 242 | 9 | 1.7 (0.8–3.0) |
| ⩾40 | 255 | 3890 | 2 | 18.9 (2.3–68.2) | 4.9 (0.4–18.3) | 191 | 1 | 0.4 (0.0–2.0) | 84 | 2 | 0.8 (0.2–2.6) |
| Treatment period | |||||||||||
| 1965–1975 | 332 | 5573 | 8 | 32.4 (14.0–63.8) | 13.5 (5.6–27.0) | 184 | 7 | 2.1 (0.9–4.1) | 157 | 8 | 2.4 (1.1–4.5) |
| 1976–1985 | 790 | 15 787 | 16 | 13.7 (7.8–22.3) | 9.4 (5.1–15.7) | 650 | 6 | 0.8 (0.3–1.6) | 569 | 16 | 2.1 (1.2–3.3) |
| 1986–1995 | 811 | 11 564 | 14 | 10.1 (5.5–16.9) | 10.9 (5.4–19.1) | 716 | 11 | 1.4 (0.7–2.4) | 84 | 14 | 1.8 (1.1–3.0) |
| Total treatmentb | |||||||||||
| Surgeryc | 740 | 14 620 | 25 | 23.2 (15.0–34.3) | 16.4 (10.3–24.5) | 646 | 16 | 2.2 (1.3–3.5) | 382 | 25 | 3.7 (2.4–5.3) |
| Platinum-based CTc,f | 940 | 15 034 | 12 | 7.9 (4.1–13.7) | 7.0 (3.1–12.9) | 778 | 8 | 0.9 (0.4–1.6) | 321 | 12 | 1.4 (0.7–2.3) |
| Other CTc | 253 | 3450 | 1 | 5.0 (0.1–27.6) | 2.3 (−0.5 to 15.6) | 126 | 0 | 0.0 | 107 | 1 | 0.4 (0.0–2.1) |
| Follow-up interval (years)d,e | |||||||||||
| 0.5–4 | 1993 | 7694 | 11 | 16.5 (8.2–29.5) | 13.4 (6.3–24.7) | ||||||
| 5–9 | 1621 | 7950 | 13 | 16.2 (8.6–27.6) | 15.3 (7.7–27.0) | ||||||
| 10–14 | 1550 | 7075 | 8 | 11.7 (5.0–23.0) | 10.3 (3.9–21.3) | ||||||
| 15–19 | 1233 | 5162 | 6 | 15.2 (5.6–33.0) | 10.9 (3.5–11.3) | ||||||
| 20–24 | 810 | 3099 | 0 | 0.0 (0.0–21.1) | −0.4 (−0.4 to 24.7) | ||||||
Abbreviations: AER=absolute excess risk; 95% CI=95% confidence interval; CTGCT=contralateral testicular germ cell tumour; CT=chemotherapy; SIR=standardised incidence ratio; TGCT=testicular germ cell tumour.
a
Includes three patients, two seminoma and one non-seminoma, with a non-testis second cancer (two stomach cancers, treated with surgery only, and one lung cancer) before the CTGCT diagnosis.
b
Includes treatment for relapse/recurrence before metachronous CTGCT diagnosis.
c
With or without radiotherapy.
d
Number at risk at begin of interval.
e
Person-time in follow-up interval ⩾25 years: 2305 for seminoma and 2123 years for non-seminoma (4428 for combined group).
f
Two patients with 2xBEP (Bleomycin, Etoposide, Cisplatin), one patient with 3xBEP+1xEP (Etoposide, Cisplatin), four patients with 4xBEP, one patient with 4xEP, one patient with 4xCEB (Carboplatin, Etoposide, Bleomycin), one patient with 4xVIP (Etoposide, Ifosfamide, Cisplatin), three patients with 4xPVB (Cisplatin, Vinblastin, Bleomycin).